Table 2. Risk management options given as percentages undertaken by women at baseline and in the 3 years post-testing according to carrier status and age.

		3 year follow-up
	Baseline	N=154
Age group	N=227	Carrier (n=53)	Non-carrier (n=101)
Mammography
<35	29	81	22
35–49	46	91	44
>50	61	100	65
Total	45	89	46
BRRM*
<35	2	38	0
35–49	2	38	0
⩾50	0	0	0
Total	1	34	0
BRRO+
<35	2	25	0
35–49	10	54	3
>50	30	40	7
Total	13	43	3
Breast biopsy *
<35	Not asked	19	9
35–49		19	2
⩾50		20	6
Total		19	5
Ovarian biopsy+
<35	Not asked	13	0
35–49		4	0
>50		0	4
Total		6	1
Ovarian US+
<35	8	81	5
35–49	32	75	16
⩾50	26	60	25
Total	43	75	17
CBE
<35	35	88	39
35–49	48	81	51
⩾50	48	100	38
Total	45	85	44
Tamoxifen
<35	0	0	0
35–49	2	6	0
⩾50	10	20	6
Total	3	6	2
BrSE
<35	85	81	100
35–49	91	97	98
⩾50	83	100	88
Total	88	91	95

Figures exclude patients who have had BRRM (^*) or BRRO (+) as appropriate.